RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

• Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions
   
• PPIs are one of the most commonly prescribed classes of medications in the U.S., with an estimated market value exceeding $20 billion in 2016
   
• RedHill’s GI-focused sales force, headquartered in Raleigh, NC, promotes three GI-specialty products in the U.S., Donnatal^®, EnteraGam^® and Esomeprazole Strontium DR Capsules 49.3 mg 

TEL-AVIV, Israel and RALEIGH, N.C., Sept 14 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases and cancer, today announced that it has initiated promotion of Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg¹ in the U.S.

RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, includes a gastrointestinal-focused sales force of approximately 40 sales representatives promoting three gastrointestinal (GI)-specialty products, Donnatal^® (Phenobarbital, Hyoscyamine Sulfate, Atropine Sulfate, Scopolamine Hydrobromide)², EnteraGam^® (serum-derived bovine immunoglobulin/protein isolate, SBI)³ and Esomeprazole Strontium DR Capsules 49.3 mg in select U.S. territories. RedHill’s U.S. commercial operations are expected to pave the way for the potential future launch of RedHill’s late clinical-stage GI products, if approved by the U.S. Food and Drug Administration (FDA).

Source : RedHill Biopharma Ltd.